Genoks and Velsera Forge Strategic Partnership to Revolutionize Cancer Diagnostics in Turkey
2024年6月28日 - 2:04PM
ビジネスワイヤ(英語)
Empowering clinicians to make informed
treatment decisions tailored to each patient's unique genetic
profile.
Genoks, a leading Turkish genomics healthcare company, and
Velsera, a global healthcare technology company offering a
universal software platform to connect clinical care with
discovery, have announced a collaboration aimed at advancing cancer
diagnostics and treatment in Turkey and nearby regions.
This strategic partnership combines Genoks' expertise in
genomics with Velsera's innovative Clinical Genomics Workspace
(CGW), a cutting-edge platform designed for comprehensive analysis
of data obtained from solid tissue and liquid tumor as well as
hematological cancer samples. Leveraging Velsera's capabilities in
genomic analysis and data interpretation, Genoks will integrate CGW
into its cancer diagnostic services, enhancing its ability to
detect and characterize various types of cancer accurately.
"We are thrilled to partner with Velsera in our shared mission
to revolutionize cancer diagnostics and treatment in Turkey and
beyond,” said Dr. Yunus Alp, MD Clinical Geneticist of Genoks.
"Together, we are poised to make a significant impact in the fight
against cancer, empowering clinicians with precise insights to
guide treatment decisions and improve patient outcomes."
The Clinical Genomics Workspace is tailored for physicians and
clinical laboratory professionals specializing in oncology and
inherited diseases. It aims to dismantle obstacles hindering the
establishment or growth of their Next-Generation Sequencing (NGS)
testing programs. Whether it's physician-owned laboratories, large
hospitals, or reference labs, CGW empowers molecular diagnostics
experts worldwide to thrive.
By joining forces, Genoks seeks to advance its position as a
leader in oncology diagnostics in Turkey, providing patients and
healthcare providers with state-of-the-art testing solutions for
precise and personalized cancer care. The advanced algorithms and
tools provided by Velsera will empower Genoks to deliver precise
and actionable insights, enabling clinicians to make informed
treatment decisions tailored to each patient's unique genetic
profile.
This collaboration marks a significant milestone in the field of
oncology, underscoring the pivotal role of strategic partnerships
in accelerating cancer research and elevating the standard of
patient care. With a shared dedication to innovation and
excellence, Genoks and Velsera stand ready to make a profound and
enduring impact on the fight against cancer in Turkey and across
borders.
About Genoks
Since its establishment in 2008, Genoks has proudly represented
Turkey in the international genomics market, providing DNA and RNA
sequencing, solid/liquid cancer screening services with its team of
experts and state-of-the-art equipment. Sharing its technology with
approximately 7,000 users in more than 15 countries, Genoks has
conducted over 180,000 Next Generation Sequencing (NGS) analyses to
date while actively participating in research and development
projects. With new technology transfers and advancements, Genoks
aims to reach more people and provide solutions in the field of
personalized health care. For more information, visit
onkogenoks.com and global.genoks.com.tr
About Velsera
Velsera’s mission is to be the discovery, evidence generation,
and clinical delivery platform for precision medicine. We help
experts in clinical diagnostics and life sciences make better
decisions about providing the right therapy to the right patients
at the right time. Velsera was founded in 2023 as a result of the
merger of Seven Bridges, PierianDx and UgenTec and operates in the
US, Europe and Asia. For more information, visit
www.velsera.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240628892797/en/
Nafiseh Nesbat, PhD. Manager, Oncology Department Genoks
nafiseh.nesbat@genoks.com.tr (+90) 552 952 32 45
Brian Lassiter Manager, Commercial Marketing Velsera
brian.lassiter@velsera.com (857) 357-3060 | ext 3060